Scope
The official highlights of the multisociety dyslipidaemia guideline emphasise earlier prevention, PREVENT-based risk assessment, renewed cholesterol goals and selective use of additional biomarkers and coronary calcium. This is a focused account of the published highlights, not the full drug-selection or risk-classification algorithm.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Address cumulative lipid exposure early
- Begin lifestyle counselling in youth. Consider medication early for young people with familial hypercholesterolaemia, and in young adulthood when LDL cholesterol is at least 160 mg/dL or there is a strong family history of premature atherosclerotic cardiovascular disease. [1]
- For primary prevention in adults aged 30–79 years, use PREVENT rather than the older pooled cohort equations for assessment of ten-year and thirty-year cardiovascular risk. [1]
- Use the calculate–personalise–reclassify approach: calculate PREVENT atherosclerotic risk, consider additional patient factors, and selectively use coronary calcium to reclassify risk and revisit treatment. [1]
Use risk and clinical conditions to guide treatment
- After clinician–patient discussion, LDL-lowering treatment can be considered at a ten-year PREVENT-ASCVD risk of 3% to below 5%, and should be considered at 5% to below 10%. Preserve this distinction between borderline and intermediate risk. [1]
- Use LDL and non-HDL cholesterol goals alongside the percentage LDL reduction when guiding therapy. The required percentage reduction depends on the patient’s atherosclerotic risk; the highlights do not supply every category-specific target. [1]
- Recommend LDL-lowering treatment for primary prevention in adults aged 40–75 years with diabetes, stage 3 or 4 chronic kidney disease, or HIV, regardless of their LDL cholesterol level. [1]
- After age 75, lipid-lowering medication may be considered together with lifestyle measures. The source frames this as a consideration, rather than extending the younger-age recommendation automatically. [1]
Use additional lipid and imaging measurements selectively
- Consider apolipoprotein B after LDL and non-HDL goals have been achieved, particularly with triglycerides above 200 mg/dL, diabetes, or achieved LDL below 70 mg/dL. It can identify residual lipoprotein-related risk missed by the usual lipid profile. [1]
- Measure lipoprotein(a) at least once. A level of at least 125 nmol/L or 50 mg/dL is a risk-enhancing finding; elevated values support more intensive LDL lowering and management of other risk factors. [1]
- Selective coronary calcium scoring can refine risk in men aged at least 40 and women aged at least 45. Interpret both the absolute calcium burden and its standardised percentile when reconsidering treatment goals. [1]
Apply the reported secondary-prevention targets
- For secondary prevention in people at very high risk of atherosclerotic events, the stated goals are LDL cholesterol below 55 mg/dL and non-HDL cholesterol below 85 mg/dL. The highlights do not reproduce the full criteria defining very high risk. [1]
- Do not apply the very-high-risk target indiscriminately to every patient with atherosclerotic disease: the overview also identifies a smaller group outside that category with an LDL goal below 70 mg/dL. [1]
Separate cardiovascular prevention from pancreatitis prevention
- For persistently high triglycerides, retain statins as the pharmacological foundation for reducing atherosclerotic risk alongside lifestyle changes. [1]
- Consider triglyceride-lowering treatment for pancreatitis prevention, particularly when triglycerides are at least 1000 mg/dL. This focused source does not specify a drug selection or dosing protocol. [1]
Limitations and use
- This summary covers selected recommendations in the AHA public highlights. It does not provide the full guideline’s drug doses, eligibility criteria, exceptions or evidence tables.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Management of dyslipidaemia — focused recommendation source
Selected recommendation material consulted
Publication details
- Issuing organisation
- ACC / AHA
- First published
- 13 March 2026
- Resource type
- Clinical guideline · House clinical summary
Earlier House summaries: dyslipidaemia management aha
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.